Postmenopausal hypertension

被引：37

作者：

Harrison-Bernard L.M. ^{[1
]}

Raij L. ^{[2
]}

机构：

[1] Department of Physiology SL39, Tulane University, School of Medicine, New Orleans, LA 70112-2699

[2] Nephrology Section 111J, Veterans Affair Medical Center, University of Minnesota, Minneapolis, MN 55417, One Veterans Drive

来源：

Current Hypertension Reports | 2000年 / 2卷 / 2期

关键词：

Nitric Oxide; Estrogen; Postmenopausal Woman; Reduce Blood Pressure; Ambulatory Blood Pressure Monitoring;

D O I：

10.1007/s11906-000-0083-2

中图分类号：

学科分类号：

摘要：

Cardiovascular disease is the leading cause of death in women and claims the lives of more than half a million women every year. Hypertension is one of the most prevalent and powerful contributors to atherosclerotic cardiovascular disease. Hypertension affects more men than women until 55 years of age, but after age 55, the percentage of women is higher. Estrogen deficiency has been linked to the rapid increase in cardiovascular disease in women who have undergone natural or surgical menopause. Hormone replacement therapy (HRT) has been shown to decrease the incidence of cardiovascular disease and, in some studies, to reduce blood pressure in postmenopausal women. However, little information is available on the effects of HRT on blood pressure in hypertensive postmenopausal patients. The cardioprotective effects of estrogens are not completely understood but may involve direct effects on blood vessels through modulation of endogenous vasoconstrictors and vasodilators and through reductions in serum lipoprotein and cholesterol levels. Experimental evidence suggests that estrogen increases the biological actions of nitric oxide and decreases the actions of angiotensin. After menopause, loss of the vascular protective effects of estrogens may unmask a population of women particularly prone to hypertension who would be at higher risk for cardiovascular disease. Copyright © 2000 by Current Science Inc.

引用

页码：202 / 207

页数：5

共 52 条

[1]

Glendy R.E., Levine S.A., White P.D., Coronary disease in youth, JAMA, 109, pp. 1775-1781, (1937)

[2]

Mosca L., Manson J.E., Sutherland S.E., Et al., Cardiovascular disease in women: A statement for healthcare professionals from the American Heart Association Writing Group, Circulation, 96, pp. 2468-2482, (1997)

[3]

Kannel W.B., Wilson P.W., Risk factors that attenuate the female coronary disease advantage, Arch Intern Med, 155, pp. 57-61, (1995)

[4]

Sullivan J.M., Fowlkes L.P., The clinical aspects of estrogen and the cardiovascular system, Obstet Gynecol, 87, (1996)

[5]

Kannel W.B., Hjortland M.C., McNamara P.M., Et al., Menopause and risk of cardiovascular disease: The Framingham Study, Ann Intern Med, 85, pp. 447-452, (1976)

[6]

Stampfer M.J., Colditz G.A., Willett W.C., Et al., Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the Nurses' Health Study, N Engl J Med, 325, pp. 756-762, (1991)

[7]

Pines A., Mijatovic V., Van Der Mooren M.J., Et al., Hormone replacement therapy and cardioprotection: Basic concepts and clinical considerations, Eur J Obstet Gynecol Reprod Biol, 71, pp. 193-197, (1997)

[8]

Grodstein F., Stampfer M.J., Manson J.E., Et al., Postmenopausal estrogen and progestin use and the risk of cardiovascular disease, N Engl J Med, 335, pp. 453-461, (1996)

[9]

Wren B.G., The effect of oestrogen on the female cardiovascular system, Med J Aust, 157, pp. 204-208, (1992)

[10]

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) trial, JAMA, 273, pp. 199-208, (1995)

← 1 2 3 4 5 6 →